Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Steris plc

NYSE: STE · Industrial Applications and Services · 7 alerts · CIK 1757898

Share price
$261.91Close, Nov 16
Market cap
$25.4B
Shares outstanding
97.11MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Steris plc filings on SEC EDGAR ↗

4:32 PM ET Form 4
Insider Selling

Steris Sr. Vice Pres., CFO Karen L. Burton Sells $1.5M of Stock

Karen L. Burton, Sr. Vice Pres., CFO, sold 5,880 shares of Steris plc at $255.62 a share, worth $1.5M in total on Nov 11, 2026. Shares held after the trade: 12,956 (-31.2%).

Value
$1.5M
Shares
5,880
Price
$255.62
Role
Sr. Vice Pres., CFO
Holding change
-31.2%
Trade date
Nov 11, 2026
4:32 PM ET Form 4
Insider Selling

Steris Insider Mohsen Sohi Sells $1.24M of Stock

Mohsen Sohi sold 4,893 shares of Steris plc at $252.87 to $253.90 a share (average $253.22) in 2 transactions, worth $1.24M in total on Nov 10, 2026. Shares held after the trade: 24,305 (-6.4%).

Value
$1.24M
Shares
4,893
Average price
$253.22
Holding change
-6.4%
Trade date
Nov 10, 2026
4:10 PM ET 8-K
Loan & Debt

Steris $1.5B Debt Financing with J.P. Morgan Securities LLC

STERIS plc's subsidiary, STERIS Irish FinCo Unlimited Company, priced an offering of $1.5 billion in senior notes, consisting of $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. The proceeds will be used to fund the pending acquisition of Xodus Medical, Inc., transaction expenses, and general corporate purposes.

Value
$1.5B
Counterparty
J.P. Morgan Securities LLC
4:04 PM ET 10-Q
Financial Results

Steris Q2 2026 Results: Net Income $214M, Up 11.4% YoY

STERIS plc reported total revenues of $1,588.6 million for the quarter ended September 30, 2026, an 8.8% increase compared to the prior year. Net income attributable to shareholders rose to $213.7 million, driven by growth in both product and service segments, while the company continued its share repurchase program with $215.9 million spent in the first six months of the fiscal year.

Key figure
Net income $214M · +11.4% YoY
5:13 PM ET 8-K
Loan & Debt

Steris $1.6B Debt Financing with JPMorgan Chase Bank, N.A.

STERIS plc entered into a new $1.6 billion revolving credit agreement with JPMorgan Chase Bank and other lenders, replacing its existing 2024 facility. The new facility matures on November 4, 2031, and includes an accordion feature allowing for an incremental increase of up to $800 million. The proceeds will be used for general corporate purposes, including swingline borrowings and letters of credit.

Value
$1.6B
Counterparty
JPMorgan Chase Bank, N.A.
Term
5 years
4:41 PM ET 8-K
Financial Results

Steris Financial Results

STERIS reported fiscal 2027 second quarter revenue of $1.6 billion, a 9% increase driven by strong performance in the Life Sciences segment. Adjusted EPS rose to $2.94, benefiting from approximately $20 million in tariff refunds. The company raised its full-year outlook based on solid underlying demand and segment performance.

Term
Q2 2027

“Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year. Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date. Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.”

Dan Carestio, President and CEO of STERIS
4:30 PM ET 8-K
M&A Deal

Steris Signs $2.1B M&A Deal with Xodus Medical, Inc.

STERIS plc, through its subsidiary, has entered into a definitive agreement to acquire Xodus Medical, Inc., a specialty surgical products business, for $2.1 billion in cash. The deal includes potential additional earnout consideration of up to $150 million based on 2028 performance targets and is expected to close by December 31, 2026. STERIS has secured a $2.0 billion bridge financing commitment from JPMorgan and Goldman Sachs to support the acquisition.

Value
$2.1B
Counterparty
Xodus Medical, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.